FDA weighs changes to policy on advisor conflicts

FDA may loosen its conflicts-of-interest rules governing scientists who serve on its advisory committees, Commissioner Margaret Hamburg said, in an attempt to ensure that it gets enough expert feedback on potential drug approvals and safety moves. Report

Suggested Articles

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.

Eli Lilly has a pipeline stuffed with a host of assets and has decided it needs a new injectable drug and device plant to manufacture some of them.

After Clovis’ Rubraca snagged an FDA boost in prostate cancer last week, AZ and Merck’s rival Lynparza has matched it with a boost of its own.